| 2008~ | Member, Ethical Committee, Medical University of Vienna |
| 2006 | Close cooperation with Dr. Robert Kralovics (molecular genetics) in the field of chronic myeloproliferative disorders |
| 2000 | Education and approbation for coordination of GCP conformed clinical trials |
| 2000 | Successful graduation of the educational course of the Austrian Medical Council for the organization and processing of clinical studies in 2000 and regular educational courses for the update of GCP training during each new international clinical study |
| 1981~ | Staff Member, University of Vienna; Fellowship, Institute of Clinical Pathology and at the Department of Internal Medicine |
| 1995~ | Work on the signal transduction of the CD95-mediated apoptosis-pathway. Investigation of an autocrine or paracrine induced apoptosis by various cytokines (Blood 2001). Investigation of the mechanism of action of new drug combinations e.g.: “Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? (Brit J Haematol 2001)” |
| 1993-1994 | Visiting researcher at the MD Anderson Cancer Center in Houston, Texas. Research work in the group of Prof. Dr. M. Talpaz on the role of apoptosis in the pathogenesis of CML |
| 1989 | Research work: first description of the therapeutic effect of interferon alpha on lowering of platelet counts in Philadelphia-negative chronic myeloproliferative disorders (Lancet 1989) |